Blood Biomarkers Discriminate Cerebral Amyloid Status and Cognitive Diagnosis when Collected with ACD-A Anticoagulant

• DOI: 10.2174/0115672050271523231111192725
• Publication Date: 2023-12-04T10:01:29Z
• Authors: Zachary D. Green; Paul J. Kueck; Casey S. John; Jeffrey M. Burns; Jill K. Morris
• Keywords: Amyloid (mycology); Amyloid beta

Background: The development of biomarkers that are easy to collect, process, and store is a major goal research on current Alzheimer’s Disease (AD) underlies the growing interest in plasma biomarkers. Biomarkers with these qualities will improve diagnosis allow for better monitoring therapeutic interventions. However, blood collection strategies have historically differed between studies. We examined ability various ultrasensitive predict cerebral amyloid status cognitively unimpaired individuals when collected using acid citrate dextrose (ACD). then cognitive impairment independent status. Method: Using cross-sectional study design, we measured beta 42/40 ratio, pTau-181, neurofilament-light, glial fibrillary acidic protein Quanterix Simoa® HD-X platform. To evaluate discriminative accuracy determining status, used both banked 18F-AV45 PET neuroimaging data from 140 participants. further their discriminate by leveraging 42 impaired older adults. This first, as per our knowledge, examine specific tests (ACD), well relationship Results: Plasma AB42/40 had highest AUC (0.833, 95% C.I. 0.767-0.899) at cut-point 0.0706 discriminating two groups (sensitivity 76%, specificity 78.5%). NFL 20.58pg/mL (0.908, CI 0.851- 0.966) 84.8%, 89.9%). addition age apolipoprotein e4 did not Conclusion: Our results suggest Aβ42/40 ratio useful clinician-rated elevated These findings reinforce body evidence regarding general utility extend non-traditional anticoagulant.